This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application.
Read Position Statement
2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases